Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00065468
Registration number
NCT00065468
Ethics application status
Date submitted
24/07/2003
Date registered
25/07/2003
Date last updated
25/10/2012
Titles & IDs
Public title
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Query!
Scientific title
A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Query!
Secondary ID [1]
0
0
3066K1-304
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ARCC
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell
0
0
Query!
Kidney Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Interferon Alfa
Treatment: Drugs - CCI-779
Treatment: Drugs - Interferon Alfa and CCI-779
Active Comparator: A -
Experimental: B -
Experimental: C -
Treatment: Drugs: Interferon Alfa
Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
Treatment: Drugs: CCI-779
25 mg of CCI-779 given Intra Venously once per week
Treatment: Drugs: Interferon Alfa and CCI-779
15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.
Query!
Timepoint [1]
0
0
Baseline up to Month 80
Query!
Secondary outcome [1]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS based on Independent Central Review Assessment. The period from randomization until disease progression, death or date of last contact.
Query!
Timepoint [1]
0
0
Baseline, monthly until tumor progression or death (up to Month 80)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Objective Response
Query!
Assessment method [2]
0
0
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was the disappearance of all target lesions and non target lesions. PR was at least a 30 percent (%) decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Query!
Timepoint [2]
0
0
Baseline, every 2 months until tumor progression or death (up to Month 80)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Clinical Benefit
Query!
Assessment method [3]
0
0
Clinical benefit: confirmed CR or PR or had stable disease (SD) lasting at least 24 weeks. CR was the disappearance of all target lesions and non target lesions. PR was at least a 30% decrease in sum of the LD of target lesions, taking as reference the baseline sum LD. SD was having neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Query!
Timepoint [3]
0
0
Baseline, every 2 months until tumor progression or death (up to Month 80)
Query!
Secondary outcome [4]
0
0
Duration of Response (DR)
Query!
Assessment method [4]
0
0
DR: Time from first documentation of objective tumor response to first date that recurrence or progressive disease (PD) was objectively documented, taking as a reference for PD, the smallest sum LD recorded since randomization.
Query!
Timepoint [4]
0
0
Baseline, every month until tumor progression or death (up to Month 80)
Query!
Secondary outcome [5]
0
0
Time to Treatment Failure (TTF)
Query!
Assessment method [5]
0
0
TTF is defined as the time from the date of randomization to the date of PD or death, withdrawal from treatment due to an adverse event (AE), withdrawal of voluntary consent, or lost to follow-up, whichever occurred first, censored at the date of the conclusion of treatment phase.
Query!
Timepoint [5]
0
0
Baseline, every month until tumor progression or death (up to Month 80)
Query!
Secondary outcome [6]
0
0
Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST)
Query!
Assessment method [6]
0
0
The Q-Twist is not a score calculated for each participant but is defined only on a by treatment group basis. For each treatment group, it is the weighted sum of the mean durations of the health states Tox, Twist, and Relapse. Tox is defined as time with severe toxicity related to treatment; Twist: time without symptoms or toxic side effects; and Relapse: time after relapse/progression. The mean duration of each health state is calculated based on the area under the Kaplan Meier curve pertaining to that health state. There is no direct method for calculating the "dispersion" of Q-Twist, and it is typically done using bootstrap method for purposes of inference (see, e.g., Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-76). In practice, as apparently in the case with this study, the intermediate values resulting from the bootstrap exercise were not displayed.
Query!
Timepoint [6]
0
0
Baseline to Month 80
Query!
Secondary outcome [7]
0
0
European Quality of Life Health Questionnaire (EQ-5D) - Index Score
Query!
Assessment method [7]
0
0
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. EQ-5D index measured 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Range of EQ-5D index score = -0.594 to 1 where higher scores indicated a better health state.
Query!
Timepoint [7]
0
0
Baseline
Query!
Eligibility
Key inclusion criteria
- This study will be conducted in subjects with histologically confirmed, advanced
(stage IV or recurrent disease) RCC who have not received prior systemic therapy for
their disease,
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects with central nervous system (CNS) metastases
- Prior anticancer therapy for RCC
- Prior investigational therapy/agents within 4 weeks of randomization
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
626
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Newcastle
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Westmead
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Adelaide
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - Footscray
Query!
Recruitment hospital [6]
0
0
Pfizer Investigational Site - Heidelberg
Query!
Recruitment hospital [7]
0
0
Pfizer Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
- Newcastle
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3012 - Footscray
Query!
Recruitment postcode(s) [6]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [7]
0
0
3050 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Montana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Hampshire
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Aires
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Tucuman
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Buenos Aires
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Cordoba
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Mendoza
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Quilmes
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
British Columbia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Manitoba
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Nova Scotia
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Ontario
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Quebec
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Hamilton, Ontario
Query!
Country [42]
0
0
Czech Republic
Query!
State/province [42]
0
0
Brno
Query!
Country [43]
0
0
Czech Republic
Query!
State/province [43]
0
0
Prague 5
Query!
Country [44]
0
0
Former Serbia and Montenegro
Query!
State/province [44]
0
0
Novi Sad
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
NRW
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
RP
Query!
Country [47]
0
0
Greece
Query!
State/province [47]
0
0
Creete
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Patra
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Budapest
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
RM
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Foggia
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Milano
Query!
Country [53]
0
0
Latvia
Query!
State/province [53]
0
0
Daugavpils
Query!
Country [54]
0
0
Latvia
Query!
State/province [54]
0
0
Riga
Query!
Country [55]
0
0
Lithuania
Query!
State/province [55]
0
0
Vilnius
Query!
Country [56]
0
0
Mexico
Query!
State/province [56]
0
0
Nuevo Leon
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Leon Guanajuato
Query!
Country [58]
0
0
Netherlands
Query!
State/province [58]
0
0
GA
Query!
Country [59]
0
0
Netherlands
Query!
State/province [59]
0
0
Amsterdam
Query!
Country [60]
0
0
Netherlands
Query!
State/province [60]
0
0
Enschede
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Bytom
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Lodz
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lublin
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Olsztyn
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Opole
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Poznan
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Siedlce
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Warszawa
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Barnaul
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Kemerovo
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Moscow
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Obninsk
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Saint Petersburg
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
St Petersburg
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Ufa
Query!
Country [76]
0
0
Serbia
Query!
State/province [76]
0
0
Belgrade
Query!
Country [77]
0
0
Slovakia
Query!
State/province [77]
0
0
Banska Bystrica
Query!
Country [78]
0
0
Slovakia
Query!
State/province [78]
0
0
Bratislava
Query!
Country [79]
0
0
Slovakia
Query!
State/province [79]
0
0
Martin
Query!
Country [80]
0
0
Slovakia
Query!
State/province [80]
0
0
Zlina
Query!
Country [81]
0
0
South Africa
Query!
State/province [81]
0
0
Eastern Cape
Query!
Country [82]
0
0
South Africa
Query!
State/province [82]
0
0
Gauteng
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Cape Town
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Asturias
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Barcelona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Madrid
Query!
Country [87]
0
0
Sweden
Query!
State/province [87]
0
0
Göteborg
Query!
Country [88]
0
0
Sweden
Query!
State/province [88]
0
0
Stockholm
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Uppsala
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
ROC
Query!
Country [91]
0
0
Taiwan
Query!
State/province [91]
0
0
Taichung
Query!
Country [92]
0
0
Taiwan
Query!
State/province [92]
0
0
Taipei
Query!
Country [93]
0
0
Taiwan
Query!
State/province [93]
0
0
Taoyuan
Query!
Country [94]
0
0
Turkey
Query!
State/province [94]
0
0
Istanbul
Query!
Country [95]
0
0
Turkey
Query!
State/province [95]
0
0
Izmir
Query!
Country [96]
0
0
Ukraine
Query!
State/province [96]
0
0
Dnietropetrovsk
Query!
Country [97]
0
0
Ukraine
Query!
State/province [97]
0
0
Donetsk
Query!
Country [98]
0
0
Ukraine
Query!
State/province [98]
0
0
Kharkov
Query!
Country [99]
0
0
Ukraine
Query!
State/province [99]
0
0
Kiev
Query!
Country [100]
0
0
Ukraine
Query!
State/province [100]
0
0
Lviv
Query!
Country [101]
0
0
Ukraine
Query!
State/province [101]
0
0
Zaporozhye
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Lancashire
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Strathclyde
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Surrey
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Nottingham
Query!
Country [106]
0
0
Query!
State/province [106]
0
0
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is efficacy. The primary efficacy endpoint of this study
is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus],
administered intravenously [IV] once weekly and the combination of CCI-779, administered IV
once weekly with Interferon Alfa [IFN alfa] subcutaneously [SC] three times per week [TIW],
compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in
poor-prognosis subjects with advanced RCC.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00065468
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00065468
Download to PDF